ZSMR06

ZSMR06 is a novel dual-targeted "combi-molecule" designed to simultaneously inhibit poly (ADP-ribose) polymerase (PARP) and the epidermal growth factor receptor (EGFR). Developed by researchers at McGill University, it is intended to enhance the radio- and chemosensitivity of refractory tumors, particularly those expressing EGFR or harboring BRCA1/2 mutations. By combining the mechanisms of PARP inhibition (which impairs DNA repair) and EGFR inhibition (which blocks growth signaling and can induce a "contextual synthetic lethality" state), ZSMR06 aims to expand the clinical utility of PARP inhibitors beyond tumors with hereditary homologous recombination deficiencies. In preclinical studies, it has demonstrated potent growth inhibitory activity, sensitization of bladder cancer cells to radiation, and potentiation of the alkylating agent temozolomide, even in cells expressing MGMT.